M.D at Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Germany.
Prof. Dr. Hermann L. Müller is a distinguished German pediatrician and clinical researcher, renowned for his contributions to pediatric endocrinology and oncology. He currently serves as Professor of Pediatrics and Head of the Department of Pediatrics and Pediatric Hematology and Oncology at the Klinikum Oldenburg, affiliated with the Carl von Ossietzky University of Oldenburg and the European Medical School Oldenburg-Groningen. With over three decades of expertise, Prof. Müller has played a transformative role in advancing treatments for childhood craniopharyngioma and understanding long-term outcomes in pediatric oncology survivors.
Profile:
Scopus | Orcid
Education:
Prof. Müller received his initial medical education at the Universities of Marburg and Würzburg, where he specialized in general pediatrics. He further enriched his academic foundation with a prestigious postdoctoral fellowship at Stanford University Medical Center under the mentorship of Prof. Dr. Ron Rosenfeld. He then pursued advanced training in pediatric oncology, hematology, endocrinology, and diabetology at the University of Würzburg, deepening his clinical and research expertise in complex pediatric conditions.
Professional Experience:
Prof. Dr. Hermann L. Müller has extensive professional experience in pediatric medicine, with a focus on endocrinology, oncology, hematology, and diabetology. He leads the Department of Pediatrics and Pediatric Hematology and Oncology at Klinikum Oldenburg, which is part of the European Medical School Oldenburg-Groningen and the Carl von Ossietzky University of Oldenburg. He has held prominent roles in national and international research initiatives, including coordinating large-scale clinical trials on childhood craniopharyngioma and contributing to global pediatric oncology guidelines through the International Society of Paediatric Oncology (SIOP). His career combines clinical leadership, academic excellence, and impactful research.
Research Focus:
Prof. Müller’s research is primarily centered on late effects of childhood cancer, pediatric neuro-endocrinology, and hypothalamic obesity. His most influential work involves coordinating the multicenter German/European craniopharyngioma trials HIT-ENDO and KRANIOPHARYNGEOM, which enrolled over 590 patients from Germany, Austria, and Switzerland. These groundbreaking studies have substantially contributed to global knowledge about tumor biology, satiety regulation, and improved therapeutic strategies.
Leadership & Impact:
Prof. Müller served as the speaker of the Craniopharyngioma Subgroup of the International Society of Paediatric Oncology (SIOP), enhancing international collaboration and policy development in pediatric neuro-oncology. His leadership has influenced clinical protocols and fostered cross-border data sharing in rare pediatric brain tumors. As a senior academic, he mentors young clinicians and actively contributes to the development of evidence-based pediatric care.
Recognition & Contributions:
Prof. Müller’s contributions have earned him widespread recognition within the international pediatric research community. His clinical leadership and scientific rigor have not only guided clinical trials but also established new benchmarks in managing hypothalamic disorders and long-term care for cancer survivors. His work continues to inspire evidence-based practices across Europe and beyond.
Publications:
-
Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy
Scientific Reports, 2025.
-
Daytime sleepiness and health-related quality of life in patients with childhood-onset craniopharyngioma
Scientific Reports, 2025.
-
Diagnostic and therapeutic perspectives for acquired hypothalamic obesity: Experiences made in the German craniopharyngeoma trials
Journal für Endokrinologie Diabetologie und Stoffwechsel, 2025.
-
Neuroendocrine deficits and weight development before and after proton therapy in children with craniopharyngioma
Clinical Oncology, 2025.
-
Long-term quality of life and hypothalamic dysfunction after craniopharyngioma
Review Article, 2025.
-
Management of acquired hypothalamic obesity after childhood-onset craniopharyngioma—A narrative review
Review Article, 2025.
-
Prolactin serum concentrations in childhood-onset craniopharyngioma patients
Journal of Endocrinological Investigation, 2025.
-
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors
European Journal of Health Economics, 2025.
-
Metabolic complications and their mechanisms in patients with craniopharyngioma
Review Article, 2025.
-
Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): A multicentre, open-label, randomised controlled phase 3 trial
EClinicalMedicine, 2024.